lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Half the order flow today was buying. We've been trading sideways since 5/10 with accumulation occuring. You don't speak for the market but seek to represent it on this forum which gets hundreds of thousands of views per day.
We are on OTC which can be easily manipulated.
Algorithmic traders who manipulate the price down then shout "panic" anonymously on message boards isn't an objective consensus regarding the value of DCVax or an accurate assessment of management's capacity to secure approval.
Swing traders love this false narrative.
Ultimately these mundane details do not concern me as we have a landmark trial which will lead to approval. As a shareholder I expect management to get it done while my posturing, projections, and cheerleading really have no impact upon the hundreds of years of combined knowledge present in our management team, scientific advisory board, and board of directors.
Regulators at FDA must meet with NWBO then iron out the rolling BLA process prior to it beginning. NWBO can't simply start sending the modules. Moroever, each module has a deadline. This establishment of framework where both parties agree to a rolling BLA happens at a pre NDA meeting with the applicant and regulator.
Though there's no duty to disclose that this meeting happened or that the rolling BLA has been agreed to by the regulator. Management would have a duty to disclose if the regulator signaled at the pre NDA meeting, or at any time in the BLA process, if DCVax could not get approval.
Ultimately we do not know for sure where they're at with the FDA. I expect we will get more information about that FDA process once we see the journal publication. It seems clear that management are actively pursing MHRA approval in UK before FDA in the US.
The firm has been quite busy with legal matters having obtained hundreds of patents.
Thank you, Hoff. Regulators want to make the approval decision without the appearance of bias which explains why we don't see our CEO bragging about our stock price. Though the carnival barkers who claim the sky's falling are quite self-assured in their misplaced consternation.
Quiet periods are to prevent insider trading as well as accusations the firm are trying to front run (coerce) regulators. Drug approval process isn't public. Instead of accusing the firm of doing something untoward, you could do basic due diligence like many of us have over many years. I don't see what positive contributions you make on this forum other than the chicken little routine which seems rather juvenile.
MIA investigational 21/02/2022
https://cms.mhra.gov.uk/mhra/mia/uk-miaimp-54923
Can't imagine full license will take much longer. Do regulators have lower standards for clinical trials? I doubt they want their own citizens at risk when it comes to manufacturing quality regardless if the product's for a trial or commercial use.
The firm has been under attack for over a decade while the drug approval process isn't public. Not being vertically integrated means their suppliers could be coerced into delaying their manufacturing process. So I think this explains why the firm has not been embracing transparency as a principle since it inherently creates potential risks that could prevent their product from getting to market. We are not selling a new over the counter analgesic but a disruptive oncology platform that could put storied multigenerational conglomerates out of business!
So I think once the journal gets published, and we see a PR campaign, with patient advocacy groups being more active, the firm will speak much more about this monumental success they achieved with DCVax. At that point I don't think we will really care as it will seem clear that approval's the obvious conclusion. When the stock price sits so low the navel gazing occurs but there's no reason for self doubt or these inane arguments because ultimately there's only one outcome.
Unless the security systems being used have unreported vulnerabilities, zero days, then that's an unlikely scenario. Even if one were present in a zero trust model a compromised device used as a vector of attack wouldn't be allowed on the network. This is all very hypothetical and unlikely but it would be nice to know our firm are thinking of these scenarios given the value present in their intellectual property.
I am not concerned about Huawei either but insider threats which should be a priority to mitigate at any firm.
If Advent's IT department deploys a zero trust model of information security then that should insulate them from any malign actor. I think this should be one of the questions at the ASM as shareholders should be assured that any vendors we use are applying the most rigorous security protocols possible.
https://www.crowdstrike.com/cybersecurity-101/zero-trust-security/
Certainly worse than out of shape Elon looking white as a ghost. I am glad you think of all the embarrassing scenarios.
I am sure Cofer's familiar with methods of counterintelligence (finding spies) as well as traditional law enforcement. Yes, his contacts are probably a large reason why he was made a board member. I suspect we will see action on this front announced after the journal or regulatory approval.
I wish you were encapsulated in the same cone!
As long as you're not shirtless on TikTok you should be fine. Don't act like Elon!
We could encase the Sawston facility in a giant Faraday Cage.
Huawei are certainly a bad actor seeking to spread their 5G technology across the globe so they can spy on behalf of the Chinese Communist Party. I did send Dave an email about this as I also am not a fan of them being anywhere near our firm. However, we are not using their networking equipment to my knowledge inside our factory. Advent has employed qualified IT staff which are responsible for securing their internal networks. I trust that the same rigorous standards which the firm applied to our patents was taken for our information security procedures. Though this would be a question relevant to ask at our ASM regardless of Huawei as many actors could be attempting to engage in corporate espionage given the value of our intellectual property.
I am hoping Cofer will get to the bottom of the this after we issue our formal TLD and journal PRs. He was brought on to protect our IP and as a board member we should see public action on that front.
Thank you RRH. Window for capitalizing on asymmetrical returns ends soon!
I agree 100% we should get the Ace of Spades flowing but the firm only gets one shot so let's hope their deliberate approach will keep delivering results.
Every market maker has a well paid risk department that are subject to regular SEC scrutiny. They are required to keep records of every trade and their order book. They must prove each trade was routed at the best price.
There's no way these individuals are going to sign off on such collision with their competitors by the way!
Do people here really think that Jane Street, Citadel, GTS, et al, are all working together? They are rabid competitors each with a different strategy and firm culture.
If we went bankrupt Citadel couldn't trade our stock anymore nor could the swing traders with multiple personality disorder. No, there was only one real opposition but it's been defeated by our data.
Citadel hasn't stolen anything from me because I never sold my shares.
In my opinon a medical device manufacturer has been behind the campaign to bankrupt our firm not Citadel.
I think true longs are going to look back fondly on these days because they allowed them to acquire so many shares. The fairness of markets and conspiracies against our product are certainly topics we can talk about on somebody's yacht.
Have you had a three star Michelin chef describe to you in detail the recipe and process used to make the entrées at his restaurant?
I have never heard of a patent portfolio being described during an investor call for the same reason. Those legal documents exist to protect shareholder value. They should be explained in detail only to the patent examiners then put on a shelf only brought out to defend intellectual property before a judge.
Did you find out that Merck makes Temodar?
Citadel can make a lot more money doing things which are completely legal such as crashing the $2T crypto market. This has a high reward and no risk of upsetting regulators.
Market makers do not need to actively collude to make money trading our stock. Their algorithms spot patterns. With backtesting they can predict the best trade they should make. Given the daily volume we trade that's going to be a great way for them to make profits while not putting their entire operation as a market maker at risk. Good trading algorithms risk little capital yet make large returns.
There's certainly criminal manipulation occurring with our stock but I don't believe market makers are involved.
Institutions by their nature usually win over time because they have investment horizons not bound by the finite goals of one individual. Generational wealth isn't easy to build. If it was there would be more aristocrats. I believe though we have a better shot at that outcome than many other groups of retail investors on the market today.
Yes, it would probably take a decade to reach that level of market cap along with a joint venture helping fund other trials. Being the first pharmaceutical company to do so would be the ultimate coup. I am certainly going to wait around to see what happens. It's a horrible time in my opinion to buy any other assets.
$250 entirely possible with expanded cancer indications for DCVax-L and automation via Flaskworks. If Direct proves to efficacious, for inoperable tumors, then even higher. Keytruda, the number one drug on planet earth, only reaches 0.6% of cancer patients each year.
By the time 2018 came around Woodford had already attempted a hostile takeover, the Phase V attack severely damaged the float, and the AF had been spreading vicious lies about our technology and management team for several years. You grossly understate the landscape for what purpose I don't understand since we overcame all of this adversity which should be worth celebrating.
Short sellers literally halted trial enrollment as the firm ran out of money. When are you going to go yell at Julia Skripka Serry, the Phase V author, for the GBM patients she prevented from getting DCVax?
So much outrage against management when they were not the party responsible for literally halting the trial!
NWBO in my opinion has been subject to nearly a decade of criminal manipulation by a medical device manufacturer that's sought to prevent a superior product from entering the marketplace. I believe management did what was required to ensure approval of this revolutionary product. The ends justify the means. I am behind management 100% as should be any shareholder who wants to see patients live longer.
Dilution began after Phase V Short Seller attack published on October 28th 2015 by failed PhD candidate and Israeli national Julia Skripka Serry!
Vaspeca needed marketing and sales because it was competing with unregulated over the counter fish oil. There's no comparison here with DCVax.
You don't need to market or sell a novel therapy for an orphan cancer indication.
You need a free journal article in a top publication that speaks to the clinician directly.
You need key opinion leaders spreading the word.
Then journalists do the same.
The route taken makes perfect sense.
I didn't mean to imply you said otherwise. I was speaking to others in reply to you as the many uninformed critics certainly follow your posts. Sadly they never seem to learn!
Oncologists are not going to speak authoritatively about our trial to journalists until they have all the facts which the journal will illustrate. Once we get the formal TLD published by the firm alongside the journal we can expect sentiment to change dramatically.